EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische Übersicht

Long‐Term Durability and Safety Signals of Systemic AAV Gene Therapy for Haemophilia A and B: A Systematic Review

Mahboob Younus Shaik iD, Jay Patel iD, Sunil Kakadia iD, Stephen Divers

European Journal of Haematology · 30.10.2026

DOI: 10.1111/ejh.70348 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 30.10.2026. Verfasst von Mahboob Younus Shaik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, CHI St. Vincent Hospital, Hot Springs, Arkansas, USA. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adeno‐associated virus (AAV) gene therapy can provide sustained endogenous factor expression after a single infusion, but durability and safety differ across products. We synthesised long‐term efficacy and clinically interpretable safety outcomes while avoiding inappropriate class‐level pooling.

Methods

Five databases were searched from inception to 15 May 2026 for prospective systemic AAV trials in haemophilia A or B. Overlapping reports were linked by trial identifier, vector/transgene, dose, enrolment, sites, sample size and follow‐up. One additional eligible report published within the search window was identified during peer review and incorporated. The primary outcome was product‐specific factor activity at the latest follow‐up with clinical durability. Prophylaxis status, bleeding and safety were synthesised descriptively by product because baseline regimens, outcome definitions and observation windows were not sufficiently harmonised for cross‐product pooling. Risk of bias was assessed with ROBINS‐I.

Results

Fourteen unique cohorts were included: six in haemophilia A and eight in haemophilia B. Reported long‐term factor activity remained product‐specific. The GS001 Phase 1 study reported median FVIII activity of 5.6 IU/dL at Week 144 in the low‐dose cohort and 42.7 IU/dL at Week 104 in the high‐dose cohort. Prophylaxis and zero‐treated‐bleed outcomes were not pooled because baseline treatment, restart criteria, denominators and observation windows differed. Liver abnormalities, immunosuppressive exposure, treatment‐related serious adverse events and loss of expression varied by product. Rare inhibitor and thrombotic events reported outside the eligible prospective cohort synthesis reinforce the need for ongoing product‐specific surveillance.

Conclusions

Selected patients experienced sustained haemostatic benefit, and several FIX programmes showed stable multiyear expression. Because assays, products, immune‐management strategies and follow‐up differed, counselling and surveillance should remain product‐specific. Standardised longitudinal reporting is required for stronger comparative conclusions.

Schlagwörter

Stichwörter der Autor:innen

adeno‐associated virusdurabilitygene therapyhaemophilia Ahaemophilia Bsafetysystematic review

Autor:innen und Institutionen

  • Department of Internal Medicine, CHI St. Vincent Hospital, Hot Springs, Arkansas, USA.
  • Department of Internal Medicine, Kaweah Health Medical Center, Visalia, California, USA.
  • Genesis Cancer and Blood Institute, Hot Springs, Arkansas, USA.

ORCID-Profile: Mahboob Younus Shaik, Jay Patel, Sunil Kakadia

Zitieren

APA

Shaik, M. Y., Patel, J., Kakadia, S., & Divers, S. (2026). Long‐Term Durability and Safety Signals of Systemic AAV Gene Therapy for Haemophilia A and B: A Systematic Review. European Journal of Haematology. https://doi.org/10.1111/ejh.70348

Vancouver

Shaik MY, Patel J, Kakadia S, Divers S. Long‐Term Durability and Safety Signals of Systemic AAV Gene Therapy for Haemophilia A and B: A Systematic Review. European Journal of Haematology. 2026. doi:10.1111/ejh.70348

BibTeX
@article{Shaik2026,
  author = {Shaik, Mahboob Younus and Patel, Jay and Kakadia, Sunil and Divers, Stephen},
  title = {Long‐Term Durability and Safety Signals of Systemic AAV Gene Therapy for Haemophilia A and B: A Systematic Review},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70348}
}
Kostenlos starten →